Please assess the completion status of the following clinical trial:

Trial Title: eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is male or female, at least 18 years of age~* Subject has a diagnosis of epilepsy with partial-onset seizures according to the International Classification of Epileptic Seizures (1981)~* Subject is taking levetiracetam (LEV) in combination with 1 sodium channel blocking antiepileptic drug (defined as carbamazepine, lamotrigine, oxcarbazepine, phenytoin, or eslicarbazepine) as adjunctive treatment for epilepsy~* The minimum required seizure frequency during the 8-week Retrospective Seizure Baseline is on average ≥ 2 partial-onset seizures per 28 days with at least 1 seizure per 4 week period within the 8-week Retrospective Seizure Baseline. Additionally, subjects must experience at least 1 seizure during the 4-week Prospective Seizure Baseline~* Subject has been maintained on a stable dose of LEV and a sodium channel blocking antiepileptic drug (SCB-AED) for at least 4 weeks prior to the Screening Visit (Visit 1) and during the 4-week Prospective Seizure Baseline~* The minimum required seizure frequency during the 8-week Retrospective Seizure Baseline is on average ≥ 2 partial-onset seizures per 28 days (based on investigator assessment of subject report) with at least 1 seizure per 4 week period within the 8-week Retrospective Seizure Baseline~* Subject has been maintained on a stable dose of levetiracetam (LEV) and a sodium channel blocking antiepileptic drug (SCB-AED) for at least 4 weeks prior to the Screening Visit (Visit 1) and during the 4-week Prospective Seizure Baseline, with or without additional concurrent stable vagal nerve stimulation (VNS). The VNS must have been in place for at least 6 months prior to the Screening Visit (Visit 1) with constant settings for at least 4-weeks prior to the Screening Visit (Visit 1) and throughout the duration of the study~Exclusion Criteria:~* Previous use of lacosamide~* History of alcohol or drug abuse~* History of seizure disorder characterized primarily by isolated auras~* History of primary generalized seizures~* History of status epilepticus within the 12-months~* History of clustering seizures~* Nonepileptic events, including pseudoseizures that could be confused with seizures~* History of any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize the subject's health or would compromise the subject's ability to participate in this study~* Lifetime history of suicide attempt, or suicidal ideation in the past 6 months~* Hypersensitivity to any component of lacosamide (LCM)~* History of acute or sub-acute progressive central nervous system disease~* History of severe anaphylactic reaction or serious blood dyscrasias~* Impaired renal function (ie, Creatinine Clearance (CLcr) is lower than 30 mL/min) at Visit 1~* History of sick sinus syndrome without a pacemaker, or atrioventricular (AV) block, or subject has any other clinically significant electrocardiogram (ECG) abnormalities~* History sodium channelopathy, such as Brugada syndrome~* History of myocardial infarction in the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): Lacosamide will be added to levetiracetam while withdrawing the sodium channel blocking antiepileptic drug (AED)

Based on this trial design, predict the completion outcome and termination type (if applicable).